4basebio Plc - 4basebio는 Tier 1 제약 고객의 백신 프로그램에 opDNA™ DNA 제품을 공급한다고 발표했습니다.
4basebio Plc - 4basebio는 Tier 1 제약 고객의 백신 프로그램에 opDNA™ DNA 제품을 공급한다고 발표했습니다.
PR 뉴스 와이어
영국 런던, 10월 XNUMX일
10 4월 2024
4베이스바이오 PLC
("포베이스바이오" 또는 "회사")
4basebio announces the supply of its opDNA™ DNA products into Tier 1 Pharma client’s vaccine program
캠브리지, 영국, 10 4월 2024 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform, today announces the supply of its HQ synthetic DNA to a Tier 1 Pharma Company. Following successful completion of an opDNA™ evaluation study, our client has now progressed to HQ opDNA™ for late preclinical studies for an mRNA vaccine program. Supply of GMP grade material for clinical trials is anticipated in Q3.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.
Dr 헤이키 랑크리에트, CEO at the Company, commented: "This is a major achievement for our company and is significant both in terms of product quantity and value. It’s a clear recognition of the strengths of our synthetic DNA products, our product quality, and our manufacturing capabilities.
“There is strong interest in our synthetic DNA products, and we are now supporting a growing number of projects into the clinic. We expect client acquisition and revenue generation to continue accelerating as our expanding client base progress their clinical programs.”
추가 문의 사항은 다음으로 연락하십시오.
4베이스바이오 PLC 헤이키 랑크리에트 | +44 (0)12 2396 7943 |
추천 어드바이저 케언 금융 고문 LLP 조 튜너 / 샌디 제이미슨 | +44 (0)20 7213 0880 |
Broker 캐번디시 캐피털 마켓 리미티드 제프 내쉬 / 찰리 비슨 / 나이젤 버크스 | +44 (0)20 7220 0500 |
Lionsgate Communications(미디어 문의) 조나단 찰스 | +44 (0)77 91892509 |
편집자 주
포베이스바이오 소개
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients. The company is offering GMP compliant DNA starting materials suitable for use in AAV viral vector production as well as mRNA vaccine and therapeutics production.
미래 예측 진술
본 발표에는 4basebio의 향후 전망에 대한 특정 진술이 포함될 수 있습니다. 이사들은 자신의 기대가 합리적인 가정에 기초하고 있다고 믿지만, 미래 전망에 대한 진술은 실제 결과와 실질적으로 다른 결과를 초래할 수 있는 요인의 영향을 받을 수 있습니다.